Daniele Cattaneo
A5087305075- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Eosinophilic Disorders and Syndromes
- Acute Myeloid Leukemia Research
- Chronic Lymphocytic Leukemia Research
- Kruppel-like factors research
- HER2/EGFR in Cancer Research
- Hemoglobinopathies and Related Disorders
- Multiple Myeloma Research and Treatments
- Platelet Disorders and Treatments
- Chemotherapy-induced cardiotoxicity and mitigation
- Lung Cancer Treatments and Mutations
- Acute Lymphoblastic Leukemia research
- PI3K/AKT/mTOR signaling in cancer
- Lymphoma Diagnosis and Treatment
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Mast cells and histamine
- Renal Diseases and Glomerulopathies
- Synthesis of Tetrazole Derivatives
- Lipoproteins and Cardiovascular Health
- Bone and Joint Diseases
- Neutropenia and Cancer Infections
- Eosinophilic Esophagitis
- Pulmonary Hypertension Research and Treatments
- Autoimmune and Inflammatory Disorders
University of Milan
2016-2025
Ospedale Maggiore
2015-2025
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
2016-2025
Istituti di Ricovero e Cura a Carattere Scientifico
2014-2024
IRCCS Policlinico San Donato
2023
Policlinico S.Orsola-Malpighi
2018
University of Bologna
2018
Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda
1992
Abstract Ruxolitinib (RUX) is extensively used in myelofibrosis (MF). Despite its early efficacy, most patients lose response over time and, after discontinuation, have a worse overall survival (OS). Currently, criteria able to predict OS RUX-treated are lacking, leading uncertainty regarding the switch second-line treatments. In this study, we investigated predictors of collected 6 months RUX 209 MF participating real-world ambispective observational RUXOREL-MF study (NCT03959371)....
Background After discontinuing ruxolitinib, the outcome of patients with myelofibrosis reportedly has been poor. The authors investigated whether disease characteristics before receipt ruxolitinib may predict drug discontinuation in and reasons for discontinuation, phase at salvage therapies influence outcome. Methods A centralized electronic clinical database was created 20 European hematology centers, including laboratory data 524 who received myelofibrosis. Results At 3 years, 40.8% had...
Chronic Myeloid Leukemia (CML) patients in sustained "deep molecular response" (DMR) may stop TKI treatment without disease recurrence; however, half of them lose response shortly after withdrawing. Well-defined eligibility criteria to predict a safe discontinuation up-front are still missing. Relapse is probably due residual quiescent resistant leukemic stem cells (LSCs) supposedly transcriptionally low/silent and not easily detectable by BCR-ABL1 qRT-PCR. Bone marrow Ph+CML CD34+/CD38-LSCs...
Abstract We retrospectively studied 181 patients with polycythaemia vera ( n =67), essential thrombocythaemia =67) or primary myelofibrosis =47), who presented a first episode of splanchnic vein thrombosis (SVT). Budd–Chiari syndrome (BCS) and portal were diagnosed in 31 (17.1%) 109 (60.3%) patients, respectively; isolated the mesenteric splenic veins was detected 18 23 cases, respectively. After this index event, followed for 735 patient years (pt-years) experienced recurrences...
We report the clinical presentation and risk factors for survival in 175 patients with myeloproliferative neoplasms (MPN) COVID-19, diagnosed between February June 2020. After a median follow-up of 50 days, mortality was higher than general population reached 48% myelofibrosis (MF). Univariate analysis, showed significant relationship death age, male gender, decreased lymphocyte counts, need respiratory support, comorbidities diagnosis MF, while no association essential thrombocythemia (ET),...
Abstract Background Patients with cytopenic myelofibrosis (MF) have more limited therapeutic options and poorer prognoses compared patients the myeloproliferative phenotype. Aims Methods Prognostic correlates of phenotype were explored in 886 ruxolitinib‐treated primary/secondary MF (PMF/SMF) included RUX‐MF retrospective study. Cytopenia was defined as: leukocyte count <4 × 10 9 /L and/or hemoglobin <11/<10 g/dL (males/females) platelets <100 /L. Results Overall, 407 (45.9%) had...
Abstract Mechanisms through which mature megakaryocytes (Mks) and their progenitors sense the bone marrow extracellular matrix to promote lineage differentiation in health disease are still partially understood. We found PIEZO1, a mechanosensitive cation channel, be expressed mouse human Mks. Human mutations PIEZO1 have been described associated with blood cell disorders. Yet, role for megakaryopoiesis proplatelet formation has never investigated. Here, we show that activation of increases...
Cutaneous manifestations of hematologic malignancy represent both a clinical challenge for the treating physician and pathophysiological model advancing knowledge on individual neoplasms. Indeed, growing body evidence supports concept recurrent molecular defects associating with specific features, as best exemplified by VEXAS. Herein neutrophilic eosinophilic dermatoses potential interest hematologists dermatologists will be reviewed, including subcorneal pustular dermatosis-type IgA...
It is judged safe to discontinue treatment with tyrosine kinase inhibitors (TKI) for chronic myeloid leukemia (CML) in experimental trials on treatment-free remission (TFR). We collected a total of 293 Italian patients phase CML who discontinued TKI deep molecular response. Seventy-two percent were imatinib, and 28% second generation at the time discontinuation. Median duration last was 77 months [Interquartile Range (IQR) 54;111], median response 46 (IQR 31;74). Duration shorter than imatinib (P
Abstract Arterial occlusive events (AOEs) represent emerging complications in chronic myeloid leukemia (CML) patients treated with ponatinib. We identified 85 consecutive CML adult who were ponatinib 17 Italian centers. Patients stratified according to the Systematic Coronary Risk Evaluation (SCORE) assessment, based on sex, age, smoking habits, systolic blood pressure, and total cholesterol levels. The 60‐month cumulative incidence rate of AOEs excluding hypertension was 25.7%. Hypertension...
Abstract Patients with essential thrombocythemia (ET) are treated once‐daily low‐dose aspirin to prevent thrombosis, but their accelerated platelet turnover shortens the antiplatelet effect. The short‐term Aspirin Regimens in EsSential Thrombocythemia trial showed that twice‐daily dosing restores persistent thromboxane (TX) inhibition. However, long‐term pharmacodynamic efficacy, safety and tolerability of remain untested. We performed a multicenter, randomized, open‐label, blinded‐endpoint,...
// Alessandra Iurlo 1,2 , Emanuela Orsi 3 Daniele Cattaneo 1 Veronica Resi Cristina Bucelli Nicola Orofino Mariarita Sciumè Chiara Elena 4 Valeria Grancini Dario Consonni 5 Ester Maria Orlandi and Agostino Cortelezzi Oncohematology Division, IRCCS Ca’ Granda – Maggiore Policlinico Hospital Foundation, University of Milan, Italy 2 Unit the Elderly, Endocrinology Diabetes Unit, Department Medical Sciences, Oncology-Hematology Department, Hematology Fondazione San Matteo,...
The fibronectin EDA isoform (EDA FN) is instrumental in fibrogenesis but, to date, its expression and function bone marrow (BM) fibrosis have not been explored. We found that mice constitutively expressing the domain (EIIIA+/+), but knockout mice, are more prone develop BM upon treatment with thrombopoietin (TPO) mimetic romiplostim (TPOhigh). Mechanistically, FN binds TLR4 sustains progenitor cell proliferation megakaryopoiesis a TPO-independent fashion, inducing LPS-like responses, such as...
One out of ten patients with Philadelphia-negative myeloproliferative neoplasms (MPN) develop a second cancer (SC): in such we aimed at assessing the survival impact SC itself and MPN-specific therapies. Data were therefore extracted from an international nested case-control study, recruiting 798 diagnosed concurrently or after MPN. Overall, 2995 person-years (PYs) accumulated mortality rate (MR) since diagnosis was 5.9 (5.1-6.9) deaths for every 100 PYs. A "poor prognosis" (stomach,...
Abstract In a multicenter European retrospective study including 162 patients with COVID-19 occurring in essential thrombocythemia (ET, n = 48), polycythemia vera (PV, 42), myelofibrosis (MF, 56), and prefibrotic (pre-PMF, 16), 15 major thromboses (3 arterial 12 venous) were registered 14 patients, of whom all, but one, receiving LMW-heparin prophylaxis. After adjustment for the competing risk death, cumulative incidence venous thromboembolic events (VTE) reached 8.5% after 60 days...